Schrodinger, Inc. (SDGR) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $2.8M sold). Latest close $27.20 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 11, 2026 · Congress to Nov 16, 2026.
Rubric Capital Management · Bill & Melinda Gates Foundation Trust — 2 tracked funds hold SDGR. See all holders.
Insiders bought on the open market (0 purchases, $0) vs 8 sales ($2.8M). Insider trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Rubric Capital Management | 0.95% | 6,400,000 | ADDED (+6.7%) Q3 filed Nov 16 |
| Bill & Melinda Gates Foundation Trust | 0.33% | 6,981,664 | HELD Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +56.6% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 233 of 8,857 filers |
| Long-only filers among them | 231 |
| Change vs 2026 Q1 | +11 net · 230 entered · 219 exited |
| Shares reported, all filers | 64,708,239 |
| Reported value, all filers | $1.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $255.9M |
| Net income · FY2025 | $-103.3M |
| Total assets · FY2025 | $726.2M |
| Shares outstanding | 73,443,298 |
| Market cap (at latest close) | $2.0B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Dec 31, 2025.
| Shares short · Oct 15, 2026 | 10,402,258 |
| Share of shares outstanding | 14.16% |
| Days to cover | 3.35 |
Shares short at recent settlements — Jul 31, 2026: 11.0M · Aug 14, 2026: 11.4M · Aug 31, 2026: 11.1M · Sep 15, 2026: 11.2M · Sep 30, 2026: 10.1M · Oct 15, 2026: 10.4M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Dec 31, 2025.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 56 · Aug 14, 2026: 0 · Aug 31, 2026: 11K · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Dec 31, 2025.
0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 8 sales by 3 insiders ($2.8M).
Source: SEC Form 4 filings. Open-market transactions only.
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Abel Robert Lorne | See Remarks | Sell | 21,927 | $34.00 | $745.5K | SEC filing |
| Nov 11, 2026 | Abel Robert Lorne | See Remarks | Sell | 1,678 | $34.00 | $57.1K | SEC filing |
| Nov 9, 2026 | Tran Yvonne | EVP, CLO & CPO | Sell | 400 | $29.97 | $12.0K | SEC filing |
| Nov 9, 2026 | Tran Yvonne | EVP, CLO & CPO | Sell | 2,100 | $31.45 | $66.1K | SEC filing |
| Nov 9, 2026 | Tran Yvonne | EVP, CLO & CPO | Sell | 7,901 | $32.64 | $257.9K | SEC filing |
| Nov 9, 2026 | Tran Yvonne | EVP, CLO & CPO | Sell | 21,599 | $33.11 | $715.2K | SEC filing |
| Sep 17, 2026 | Akinsanya Karen | See Remarks | Sell | 10,000 | $28.00 | $280.0K | SEC filing |
| Sep 17, 2026 | Akinsanya Karen | See Remarks | Sell | 21,599 | $30.00 | $648.0K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | KAREN OLUFUNMILYO AKINSANYA-AKIWUMI | Officer | 31,599 | $756.2K | Sep 17, 2026 | SEC filing |
| Jul 16, 2026 | Jain Rachit | Officer | 875 | $13.6K | Jul 16, 2026 | SEC filing |
| Jul 1, 2026 | Aklian Mannix Vartan | Officer | 1,136 | $18.9K | Jul 1, 2026 | SEC filing |
| May 1, 2026 | Herman Jenny | Officer | 1,957 | $24.0K | May 1, 2026 | SEC filing |
| Apr 16, 2026 | Jain Rachit | Officer | 844 | $10.8K | Apr 16, 2026 | SEC filing |
| Apr 16, 2026 | RAMY SAMIR FARID | Director, Officer | 86,000 | $1.1M | Apr 16, 2026 | SEC filing |
| Mar 6, 2026 | Herman Jenny | Officer | 608 | $7.8K | Mar 6, 2026 | SEC filing |
| Mar 5, 2026 | Lorton Kenneth Patrick | Officer | 1,222 | $15.8K | Mar 5, 2026 | SEC filing |
| Mar 5, 2026 | Tran Yvonne | Officer | 1,094 | $14.1K | Mar 5, 2026 | SEC filing |
| Mar 5, 2026 | Herman Jenny | Officer | 775 | $10.0K | Mar 5, 2026 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 15, 2026 | Rubric Capital Management LP | SC 13G/A | 6,000,000 | 9.3% | Mar 31, 2026 | SEC filing |
| Apr 30, 2026 | Sumitomo Mitsui Trust Group, Inc. | SC 13G/A | 3,190,837 | 4.9% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Portfolio Management | SC 13G | 3,911,087 | 6.0% | Mar 31, 2026 | SEC filing |
| Mar 27, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Feb 13, 2026 | Rubric Capital Management LP | SC 13G/A | 4,171,498 | 6.5% | Dec 31, 2025 | SEC filing |
| Oct 27, 2025 | Sumitomo Mitsui Trust Group, Inc. | SC 13G/A | 4,554,569 | 7.1% | Sep 30, 2025 | SEC filing |
| Jul 18, 2025 | BlackRock, Inc. | SC 13G/A | 8,164,484 | 12.7% | Jun 30, 2025 | SEC filing |
| Feb 13, 2025 | Rubric Capital Management LP | SC 13G/A | 5,000,000 | 7.8% | Dec 31, 2024 | SEC filing |
| Feb 4, 2025 | Sumitomo Mitsui Trust Group, Inc. | SC 13G | 3,510,518 | 5.5% | Dec 31, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).
Federal contracts: $2.0M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $382.4K |
| FY2022 | $885.6K |
| FY2023 | $669.2K |
| FY2024 | $64.5K |
| FY2025 | $0 |
| FY2026 | $-4.0K |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 75N95022P00669 | Department of Health and Human Services | $247.5K | Sep 23, 2022 |
| 75N91021P00674 | Department of Health and Human Services | $18.1K | Jul 28, 2021 |
| 15DDHQ24P00000074 | Department of Justice | $540 | Nov 27, 2023 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
Key figures
· Distress Risk (Altman Z″) — Z″-Score: -0.33 · Working capital / assets: 0.45 · Retained earnings / assets: -0.87 · EBIT / assets: -0.23 · Equity / liabilities: 1.01
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
Also held by the tracked funds that hold SDGR — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 4, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 5, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Jun 29, 2026 | 7.01 Regulation FD Disclosure | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on SDGR
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.